Product Description

PANOQUELL®-CA1 (fuzapladib sodium for injection) is the first FDA conditionally approved treatment for the management of clinical signs associated with acute onset of pancreatitis in dogs. PANOQUELL-CA1 is an LFA-1 activation inhibitor. It inhibits the infiltration of neutrophilic inflammation within the pancreas that occurs in ACP. It is fast and effective by significantly reducing clinical signs associated with ACP. This will aid in reducing time and stress often seen in the hospital set.

Features & Benefits

• Is reconstituted and should be given once daily for three consecutive days by IV bolus injection